FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ARMISTICE CAPITAL, LLC		 2. Issuer Name and Ticker or Trading Symbol

ReShape Lifesciences Inc. [ RSLS ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

510 MADISON AVENUE, 7TH FLOOR, 		 3. Date of Earliest Transaction (MM/DD/YYYY)

4/13/2020
(Street)

NEW YORK, NY 10022
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 4/13/2020  X  2516667 A$0.12 2728335 D (1) 
Common Stock 4/13/2020  X  0 A$0 2728335 I See Footnote 1 
Common Stock 4/13/2020  X  2569167 A$0.12 5297502 D (1) 
Common Stock 4/13/2020  X  0 A$0 5297502 I See Footnote 1 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series C Prefunded Warrants $0.12 4/13/2020  X     2516667   (3) (3)COMMON STOCK 2516667 $0.12 0 D (1) 
Series C Prefunded Warrants $0.12 4/13/2020  X     0   (3) (3)COMMON STOCK 0 $0 0 I See Footnote 1 
Series F Prefunded Warrants $0.12 4/13/2020  X     2569167   (4) (4)COMMON STOCK 2569167 $0.12 0 D (1) 
Series F Prefunded Warrants $0.12 4/13/2020  X     0   (4) (4)COMMON STOCK 0 $0 0 I See Footnote 1 
Series G Warrants $3.70 (2)          3/25/2020 3/25/2025 COMMON STOCK 1200000  1200000 D (1) 
Series G Warrants $3.70 (2)          3/25/2020 3/25/2025 COMMON STOCK 0  1200000 I See Footnote 1 
Series E Warrants $6.00           9/23/2019 11/12/2020 COMMON STOCK 2625000  2625000 D (1) 
Series E Warrants $6.00           9/23/2019 11/12/2020 COMMON STOCK 0  2625000 I See Footnote 1 
Series A Warrants $2.64           6/18/2019 11/12/2024 COMMON STOCK 2625000  2625000 D (1) 
Series A Warrants $2.64           6/18/2019 11/12/2024 COMMON STOCK 0  2625000 I See Footnote 1 
Explanation of Responses:
(1) The reported securities are directly owned by Armistice Capital Master Fund Ltd., a Cayman Islands corporation (the "Master Fund"), and may be deemed to be indirectly beneficially owned by Armistice Capital, LLC ("Armistice Capital") as the investment manager of the Master Fund. The reported securities may also be deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Steven Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(2) On March 31, 2020, the Issuer and the Master Fund agreed to amend the terms of the Series G Warrants. Pursuant to that amendment, the exercise price of each Series G Warrant is now $3.70.
(3) The exercised Series C Prefunded Warrants had a perpetual term.
(4) The exercised Series F Prefunded Warrants had a perpetual term.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10022
X

Armistice Capital Master Fund Ltd.
C/O DMS CORPORATE SERVICES LTD.
20 GENESIS CLOSE, P.O. BOX 314
GRAND CAYMAN, E9 KY1-1104
X

Boyd Steven
C/O ARMISTICE CAPITAL, LLC
510 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10022
X
Signatures
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member4/15/2020
**Signature of Reporting PersonDate

Armistice Capital Master Fund Ltd. By: /s/ Steven Boyd, Director4/15/2020
**Signature of Reporting PersonDate

/s/ Steven Boyd4/15/2020
**Signature of Reporting PersonDate